Impact of an Electronic Health Record Maintenance Alert on PSA Screening Rates in a 10-Hospital Integrated Health System
NCT07109427
Recruiting
- The investigators propose a clinical trial to evaluate the impact of annual shared decision making for PSA screening, supported by system-level enhancements to promote evidence-based care: * Defined referral thresholds within the health maintenance reminder, aligned with clinical risk stratification per NCCN guidelines. * Enhanced clinical decision support (CDS) tools to reduce provider variation and ensure guideline-concordant screening and referral practices. * The goal is to reduce late-st... Read More
Gender:
MALE
Ages:
Between 40 years and 75 years
Trial Updated:
08/12/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Prostate Cancer, Cancer of the Prostate
Register for Updates
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
NCT04895709
Recruiting
The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab or docetaxel in participants with advanced solid tumors. This study is a first-in-human (FIH) study of BMS-986340 in participants with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Community Cancer Institute, Clovis, California +49 locations
Conditions: Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Urothelial Carcinoma, Pancreatic Adenocarcinoma, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms
Register for Updates
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
NCT04862663
Recruiting
A Phase Ib/III Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
08/12/2025
Locations: Research Site, Tucson, Arizona +279 locations
Conditions: Locally Advanced (Inoperable) or Metastatic Breast Cancer
Register for Updates
A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes
NCT07112872
Recruiting
This multicenter, randomized, double-blind, placebo- and open-label active comparator-controlled, parallel-group, dose-range-finding, Phase II study aims to evaluate the efficacy, tolerability, and safety of RO7795081 for glycemic control in adult participants with Type 2 diabetes mellitus (T2D).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Emerson Clinical Research Institute, Washington, District of Columbia +5 locations
Conditions: Type 2 Diabetes Mellitus
Register for Updates
Accelerated rTMS vs. Sham for Stroke Apathy
NCT07113067
Recruiting
Apathy is a common set of symptoms seen in many people following a stroke. Apathy occurs when a person has lost motivation, becomes withdrawn, and stops doing things that used to be important to them. Apathy has a large negative impact on a person's quality of life, and can also have a large impact the people who take care of them. There are currently no FDA-approved treatments to help with apathy, and other services like therapy may be difficult to access for people who have had a stroke. To ad... Read More
Gender:
ALL
Ages:
40 years and above
Trial Updated:
08/12/2025
Locations: Medical University of South Carolina Brain Stimulation Lab, Charleston, South Carolina
Conditions: Apathy, Stroke, Stroke Sequelae, Stroke/Brain Attack, Stroke/ Cerebrovascular Accident (Ischemic or Hemorrhagic), Motivation, Abulia
Register for Updates
Trial of Oral Digoxin in Individuals With Amyotrophic Lateral Sclerosis (ALS)
NCT07047209
Recruiting
This clinical trial is being conducted to learn about safety and tolerability of digoxin in ALS individuals. Additionally, this trial aims to better understand if digoxin has an effect on slowing neurodegeneration in ALS.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Nova Southeastern University, Davie, Florida +2 locations
Conditions: ALS (Amyotrophic Lateral Sclerosis)
Register for Updates
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
NCT07076407
Recruiting
X-NOVA3 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)
Gender:
ALL
Ages:
Between 18 years and 74 years
Trial Updated:
08/12/2025
Locations: California Neuroscience Research, Sherman Oaks, California +2 locations
Conditions: Major Depressive Disorder
Register for Updates
The RightCall: Implementing a Sepsis Diagnostic Toolkit to Improve Pediatric Diagnosis in ED Transfer Calls
NCT07051668
Recruiting
Sepsis is a leading cause of death in children, and an early diagnosis that improves outcomes is less likely in children who are treated in general Emergency Departments (EDs), that treat adults and children, compared to pediatric Emergency Departments. The study team, in collaboration with invested clinicians and expert partners, has developed a pediatric sepsis diagnostic safety toolkit that we will implement in a pediatric health system's transfer call center. Preparation for launch of the to... Read More
Gender:
ALL
Ages:
1 month and above
Trial Updated:
08/12/2025
Locations: Children's Hospital Colorado, Aurora, Colorado
Conditions: Sepsis, Diagnosis, Emergencies
Register for Updates
VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)
NCT07104383
Recruiting
This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults with Type 2 Diabetes who are obese or overweight
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Viking Clinical Site #2037, Birmingham, Alabama +111 locations
Conditions: Weight Loss
Register for Updates
Examining the Circadian Timing Effects of the Hypotensive Response to Exercise
NCT07049783
Recruiting
The goal of this study is to learn how exercise timing affects blood pressure in adults with elevated or high blood pressure. Exercise can influence the body's natural 24-hour rhythms, including blood pressure patterns. A single exercise session can lower blood pressure for up to 24 hours, but it is not fully understood how the time-of-day for exercise affects this response. The main question this study aims to answer is: • When the same participant exercises at different times of day (morning,... Read More
Gender:
ALL
Ages:
Between 18 years and 39 years
Trial Updated:
08/12/2025
Locations: University of Delaware, Newark, Delaware
Conditions: Young Adults, Hypertension, Post-Exercise Hypotension, Circadian Rhythm
Register for Updates
A Study to Evaluate Concomitant Perfluorohexyloctane Use With Contact Lens Wear
NCT07054606
Recruiting
Assess the impact of concomitant Miebo use while wearing contact lenses
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Site 101, San Diego, California +7 locations
Conditions: Dry Eye
Register for Updates
A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
NCT07071519
Recruiting
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine). This study will assess how Risankizumab moves through the body as well as how safe and effective it is in treating pediatric participants with moderate to severely active UC. Adverse events and change in disease activity will be assessed. Risankizumab is an approved medication for moderate to severe UC in multiple countries and is being... Read More
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
08/12/2025
Locations: Childrens Center For Digestive Health Care /ID# 273228, Atlanta, Georgia +2 locations
Conditions: Ulcerative Colitis
Register for Updates